Singer Jesy Nelson recently shared an emotional update regarding the complications she is experiencing in her pregnancy with twin babies. Former Little Mix singer Jesy, who is having twins with partner Zion Foster, announced that she has been diagnosed with pre-twin-to-twin transfusion syndrome (pre-TTTS). The condition, which is present in pregnancies involving twins with a shared placenta, has serious risks involved and needs intense medical supervision. As Nelson embarks on this difficult journey, her story enlightens us about a rare but dangerous condition many expectant parents may not know much about.
Twin-to-twin transfusion syndrome is a rare but dangerous condition that arises in monochorionic twin pregnancies, in which identical twins share a single placenta. The placenta supplies the developing babies with oxygen, nutrients, and blood flow, but in TTTS, there is an imbalance of blood vessels that interconnect the twins, and thus the vital resources are not evenly distributed. One twin, or the donor twin, shares excess blood with the other, referred to as the recipient twin. This leads to one baby becoming malnourished and possibly anemic, and the other in danger of heart problems due to too much blood.
Nelson described her diagnosis in a heartfelt Instagram video, explaining that she is currently in the pre-stage of TTTS and undergoing frequent monitoring. "I am being scanned twice a week, and each time, things have gotten a little worse," she shared, expressing her fears and hopes for the health of her babies.
If left untreated, TTTS can have devastating consequences. Medical research indicates that:
TTTS usually advances in stages, beginning with minimal changes in fluid levels and worsening as one twin continues to get an unequal share of blood. In extreme cases, fetal laser surgery, referred to as the Solomon technique, can be employed to divide the blood vessels and balance the twins.
Identical twins may develop differently, and their own unique form of placental sharing can have a dramatic effect on pregnancy risk. Jesy Nelson's twins are considered monochorionic diamniotic (mono/di), which means they share a placenta but have two amniotic sacs. This is the type of pregnancy in about 70% of identical twin pregnancies and carries an increased risk of complications like TTTS, umbilical cord entanglement, and growth restriction.
Conversely, dichorionic diamniotic (di/di) twins both have a separate placenta and amniotic sac, which greatly diminishes the threat of TTTS. Twin pregnancy type is normally identified by early ultrasound, with physicians being able to track future complications from inception.
Twin pregnancies, even without the presence of TTTS, entail a variety of health risks to the mother as well as infants:
Over 60% of twin pregnancies end in premature delivery, with birth usually taking place before 37 weeks. Premature infants can have immature organs and need neonatal intensive care (NICU) assistance to assist with breathing, feeding, and infection fighting.
Pregnant women with multiples are at increased risk of having high blood pressure during pregnancy. This, if left untreated, can result in preeclampsia, a serious complication of pregnancy that can result in damage to organs, preterm labor, and in some cases, maternal or fetal death.
Pregnant women carrying multiples are twice as likely to experience anemia, a condition where the body does not produce enough healthy red blood cells. This can lead to fatigue, dizziness, and complications during delivery.
According to John Hopkins Medicine, multiple birth babies are twice as likely to have congenital abnormalities compared to single births. These can include heart defects, neural tube defects, and gastrointestinal issues.
When twins have to share a placenta, they are more likely to have polyhydramnios (excess amniotic fluid) or oligohydramnios (not enough amniotic fluid). Both result in distress to the babies during fetal development and can result in premature labor.
Twins are at increased risk of excessive postpartum hemorrhage because their uterus is larger and there are greater blood supply needs.
Jesy Nelson's openness about her challenging experience is raising awareness for TTTS, a condition that few individuals—let alone expectant mothers and fathers—might be aware of. Through her tearful video, Nelson stressed the significance of knowing about twin pregnancies aside from the thrill of having multiples. "We had no idea that this type of thing occurs when you're having twins. We just desperately want to make people aware of this because there are so many people who aren't aware."
Her case reminds us of the intricacies involved in twin pregnancy and the significance of early identification and medical management. For mothers carrying twins, frequent ultrasounds and vigilance can become a life-and-death issue for early detection and better outcomes of both babies.
Through constant medical attention and care, she and her partner Zion Foster remain positive and get ready for their babies to be born. In other parents whose situations are no different, the story of Nelson highlights awareness, medical progress, and emotional encouragement in handling complicated pregnancies.
The expecting parents of twin siblings are advised to discuss TTTS screening and possible interventions with their physicians to give their babies the best chance.
India recorded 20,138 organ transplants in 2025, the highest ever in a single year, while deceased donor transplants increased to 3,526, Union Minister of State for Health and Family Welfare Anupriya Patel announced at the 16th Indian Organ Donation Day (IODD).
The Minister said India now ranks third globally in total organ transplants, after the United States and China.
Patel said the number of organ transplants increased from 4,990 in 2013 to 20,138 in 2025, marking the country's highest annual total.
She also highlighted the rise in deceased donor transplants, which increased from 837 in 2013 to 3,526 in 2025.
However, she noted that a significant gap remains between the demand for organs and their availability, adding that bridging this gap continues to be a national priority.
Describing the 16th Indian Organ Donation Day as a celebration of service and humanity, Patel said organ donation offers a second chance at life for people with end-stage organ failure.
She expressed gratitude to the families of deceased organ donors, saying their selfless decisions have strengthened India's organ donation movement.
The Minister also announced that the country has crossed five lakh Aadhaar-verified organ donation pledges
since the launch of the national digital pledge portal in 2023.
Patel said misconceptions remain one of the biggest challenges to organ donation. She stressed that no major religion prohibits organ donation and that all faiths uphold the values of compassion, service and saving lives, making organ donation a noble humanitarian act.
The national event, organised by the National Organ and Tissue Transplant Organization (NOTTO) in New Delhi, witnessed the launch of 'Jug Jug Jiyo Abhiyaan', a year-long nationwide awareness campaign aimed at taking the message of organ donation to every community and reinforcing that organ donation is the greatest gift of life.
The Minister also launched 'e-Pratyaropan, a unified digital platform that integrates hospitals, doctors, donors, recipients and other stakeholders into a single system. The platform brings together registration, wait-list management, organ allocation, monitoring and public information services.
A new NOTTO Mobile Application was also launched to improve access to organ donation and transplantation-related services and information.
The National Brain Stem Death Certification Guidelines and the National Guidelines on Swap Transplantation were also released.
The guidelines provide a practical framework for transplant professionals and support States and Union Territories in implementing a robust, ethical and efficient organ donation and transplantation programme. They are expected to strengthen the national transplantation ecosystem and facilitate wider access to safe, equitable and high-quality transplantation services across the country.
Patel said the government has established a nationwide institutional network comprising:
Credit: HHS/X.com
The United States has reported 53 new measles cases, bringing the 2026 total to 2,371, according to the latest data from the Centers for Disease Control and Prevention (CDC).
Amid the rising outbreak, US Health Secretary Robert F. Kennedy Jr. urged American parents to vaccinate their children against the highly contagious disease.
The CDC said that of the 53 new cases, 16 were locally acquired across 45 US jurisdictions, while the remaining cases were linked to international travel.
Although measles is preventable through vaccination, the 2,371 cases reported as of July 30 have already surpassed the 2,289 cases recorded during all of 2025. Both years represent the highest annual measles totals in the US since 1991.
The US was declared measles-free in 2000, but it could lose that status later this year when the Pan American Health Organization reviews transmission data.
Also read: Donald Trump Urges RFK Jr. To Accelerate Childhood Vaccine Rollback
Read More: UK Woman Becomes World-First To Receive Experimental Cell Therapy For Ovarian Cancer
In a notable shift, Kennedy urged American parents to vaccinate their children against measles during a CNN interview.
Long known as a vaccine skeptic, Kennedy has spent years amplifying misinformation about vaccines, including the measles, mumps and rubella (MMR) vaccine. His remarks came as US measles cases surpassed the 2025 annual total.
The past two years have seen more measles infections in the US than the rest of the 21st century combined. More than 90% of cases have occurred in people who are unvaccinated or whose vaccination status is unknown.
"I've never questioned the efficacy of the MMR vaccine," the Healthy Secretary said.
Kennedy also blamed low vaccination rates in some religious communities for ongoing outbreaks.
"The communities that are suffering from measles are almost all religious communities that just don't vaccinate," Kennedy told CNN.
During the interview, Kennedy also blamed pandemic lockdowns on Dr. Anthony Fauci while repeating several widely debunked claims about vaccines and other health issues.
He claimed that respiratory syncytial virus (RSV) is a major cause of infant mortality, suggested Lyme disease was caused by laboratory manipulation of germs, repeated unsupported claims linking Tylenol use during pregnancy to autism, and questioned the effectiveness of COVID-19 vaccines for children.
Large studies conducted over several decades in multiple countries have consistently found no evidence that routine childhood vaccines cause autism.
Major medical associations also continue to consider acetaminophen the preferred pain reliever and fever reducer during pregnancy when used appropriately. They have also cautioned against avoiding acetaminophen altogether, noting that untreated high fever or severe pain during pregnancy can pose risks to both the mother and the developing baby.
Speaking to CNN, Ashish Jha, former White House COVID-19 response coordinator under President Joe Biden, said the rise in measles cases was not coincidental.
"The administration has not done enough to promote vaccines. It has not done enough to highlight the harms that come from measles."
Jha added that "accountability has to be with our political leaders," while criticizing Kennedy's false claims about vaccines.
Credit: The Christie's
A 58-year-old woman in the UK has become the first person in the world to receive an experimental cell therapy for ovarian cancer.
Tracy Tomlinson, who has been living with advanced ovarian cancer for more than five years, received the first dose of ZI-MA4-1 at The Christie NHS Foundation Trust as part of the ZIMA-101 clinical trial. The study is evaluating ZI-MA4-1, the world's first MAGE-A4-targeting TCR-NK cell therapy to enter clinical development.
"While this is an early-stage study primarily focused on safety, it represents an exciting step forward in efforts to develop new treatment options for people like Tracy with advanced solid tumors. We hope the knowledge gained will help shape future cancer treatments and ultimately improve outcomes for patients," said Professor Fiona Thistlethwaite, consultant medical oncologist at The Christie.
Tracy, from Chadderton in Greater Manchester, was diagnosed with Stage 3C ovarian cancer shortly before Christmas 2020.
She first suspected something was wrong when what she thought was a urinary tract infection did not improve despite antibiotics prescribed by her GP. After blood tests, scans and further investigations, she was diagnosed with ovarian cancer just two days before her birthday.
Over the next several years, Tracy underwent surgery, multiple rounds of chemotherapy and maintenance therapy. By the summer of 2021, scans showed no evidence of disease, but the cancer returned a year later. She underwent further surgery and treatment, followed by additional recurrences.
Since 2023, Tracy has been living with ongoing cancer while receiving additional lines of treatment.
"The cancer is relentless," she said. "For me, it's never seemed to leave me alone."
Treatment has also caused fatigue, nausea and nerve damage in her hands and feet, eventually forcing her to stop working as a credit controller.
As her treatment options became more limited, Tracy began exploring clinical trials. Last year, she was referred to The Christie's early-phase clinical trials team and was eventually found eligible for the ZIMA-101 study.
After extensive screening, including scans, biopsies and blood tests, she became the first patient in the world to receive ZI-MA4-1.
"I decided almost straight away that I was going to go for it," she said. "Then afterwards you think, 'Am I doing the right thing?' because it is a little bit scary being the first person."
Following her first dose, Tracy remained in hospital for planned monitoring before being discharged on July 23.
"There are no guarantees with any trial," she said. "It could have a fantastic outcome, it could have no outcome, or somewhere in between. But if there is a possibility that it could work, I've got to go for it."
She added, "Cancer is no longer a death sentence. Five years ago, I thought I was going to die, but I'm still here."
Developed by Zelluna, ZI-MA4-1 combines two immune-based approaches to target cancer. The therapy uses natural killer (NK) cells, which can detect and destroy abnormal cells, together with engineered T-cell receptors (TCRs) that enable them to recognize tumors expressing the protein MAGE-A4.
MAGE-A4 is found in several solid tumors, including ovarian cancer, making it a promising target for precision cancer therapies.
Unlike personalized cell therapies that require a patient's own cells to be collected and manufactured individually, ZI-MA4-1 uses donor-derived immune cells and is designed as an "off-the-shelf" treatment.
Researchers hope this approach could make advanced cell therapies available to more patients in less time.
© 2024 Bennett, Coleman & Company Limited